Immunosuppressants - Bosnia and Herzegovina

Bosnia and Herzegovina

In Bosnia and Herzegovina, the Immunosuppressants market is expected to generate a revenue of US$5.38m in 2024.
It is projected to experience a steady annual growth rate (CAGR 2024-2029) of 15.12%, leading to a market volume of US$10.88m by 2029.
When compared globally, United States is anticipated to dominate the market, generating a substantial revenue of US$35,470.00m in 2024.
Bosnia and Herzegovina's immunosuppressants market is witnessing a steady growth due to an increasing prevalence of organ transplant surgeries in the country.

Key regions: Australia, Germany, United Kingdom, United States, France

Market

Region

Region comparison

Currency

Analyst Opinion

The Immunosuppressants market in Bosnia and Herzegovina has been showing notable developments in recent years.

Customer preferences: Immunosuppressants are drugs that are used to suppress the immune system, and are commonly used in the treatment of autoimmune diseases, organ transplantation, and cancer. In Bosnia and Herzegovina, there is a growing demand for immunosuppressants due to the increasing prevalence of autoimmune diseases and organ transplantation. Additionally, the rise in cancer cases in the country has also contributed to the growth of the immunosuppressants market.

Trends in the market: One of the key trends in the immunosuppressants market in Bosnia and Herzegovina is the increasing availability of generic drugs. Generic drugs are cheaper than branded drugs, and this has made them more accessible to patients who cannot afford expensive treatments. The growth of the generic immunosuppressants market has also increased competition among manufacturers, leading to lower prices and improved access to these drugs.Another trend in the market is the growing preference for biologic drugs. Biologic drugs are made from living cells and are more effective in treating autoimmune diseases and cancer. The demand for biologic drugs is increasing in Bosnia and Herzegovina due to their higher efficacy and fewer side effects compared to conventional drugs.

Local special circumstances: Bosnia and Herzegovina has a relatively small market for immunosuppressants compared to other European countries. This is due to the country's low healthcare spending and limited access to advanced medical treatments. The country also lacks a well-developed regulatory framework for the approval and distribution of drugs, which has led to the proliferation of counterfeit drugs in the market.

Underlying macroeconomic factors: The growth of the immunosuppressants market in Bosnia and Herzegovina is also influenced by broader macroeconomic factors. The country has a high burden of chronic diseases, including autoimmune diseases and cancer, which has increased the demand for immunosuppressants. Additionally, the government's efforts to improve healthcare infrastructure and increase access to medical treatments have also contributed to the growth of the immunosuppressants market. However, the country's economic instability and political uncertainty have created challenges for the healthcare sector, which may affect the growth of the immunosuppressants market in the long term.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.